Skip to main content
TipRanks
Go Ultimate75% OFF

Sun Pharmaceutical Industries Limited (SUNPHARMA) Drug Pipeline

24 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Gl0034Type Ii Diabetes MellitusPhase INot Yet RecruitingStudy to Evaluate if Exposure to Drug is Impacted in Participants With Renal InsufficiencyJan 27, 2026
Gl0034 Dose Level 1, Gl0034 Dose Level 2, Gl0034 Dose Level 3, Gl0034 Dose Level 4, Gl0034 Dose Level 5, Gl0034 Dose Level 6Type Ii Diabetes MellitusPhase IIRecruitingEfficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes MellitusDec 05, 2025―
Vehicle, Reformulated Levulan Kerastick Containing Aminolevulinic Acid Hydrochloride, 20%, Blue Light Photodynamic Therapy Illuminator Device, Blu-U Model 4170E.Actinic KeratosisPhase IIINot Yet RecruitingStudy of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper ExtremitiesAug 20, 2025
Reformulated Levulan Kerastick Containing Aminolevulinic Acid Hydrochloride, 20%, Vehicle Containing Excipients Only Without Active Ingredient, Blue Light Photodynamic Therapy Illuminator Device, Blu-U Model 4170E.Actinic KeratosisPhase IIINot Yet RecruitingStudy of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and ScalpAug 20, 2025
DeuruxolitinibAlopecia AreataPhase IIIRecruitingStudy to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia AreataJul 29, 2025
Sonidegib Phosphate CapsulesCarcinoma, Basal Cell (Bcc)Phase IVCompletedSonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in ChinaMar 12, 2025
Trifarotene Cream 0.005%, Aklief Cream Us Reference Listed Drug, Aklief Cream Canadian Reference ProductAcne VulgarisPhase ICompletedA Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne VulgarisDec 10, 2024―
Ruxolitinib Topical Cream 1.5%, Opzelura CreamAtopic DermatitisPhase ICompletedA Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.Nov 02, 2024―
Clindamycin Phosphate, Adapalene, And Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, Cabtreo Topical GelAcne VulgarisPhase ICompletedA Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.Nov 02, 2024―
Tildrakizumab 100 MgModerate To Severe Genital PsoriasisPhase IIIActive Not RecruitingA Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.Sep 23, 2024―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Sun Pharmaceutical Industries Limited (IN:SUNPHARMA) have in its pipeline
Sun Pharmaceutical Industries Limited IN:SUNPHARMA is currently developing the following drugs: Gl0034, Gl0034 Dose Level 1, Gl0034 Dose Level 2, Gl0034 Dose Level 3, Gl0034 Dose Level 4, Gl0034 Dose Level 5, Gl0034 Dose Level 6, Vehicle, Reformulated Levulan Kerastick Containing Aminolevulinic Acid Hydrochloride, 20%, Blue Light Photodynamic Therapy Illuminator Device, Blu-U Model 4170E., Reformulated Levulan Kerastick Containing Aminolevulinic Acid Hydrochloride, 20%, Vehicle Containing Excipients Only Without Active Ingredient, Blue Light Photodynamic Therapy Illuminator Device, Blu-U Model 4170E., Deuruxolitinib, Sonidegib Phosphate Capsules, Trifarotene Cream 0.005%, Aklief Cream Us Reference Listed Drug, Aklief Cream Canadian Reference Product, Ruxolitinib Topical Cream 1.5%, Opzelura Cream, Clindamycin Phosphate, Adapalene, And Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, Cabtreo Topical Gel, Tildrakizumab 100 Mg, Winlevi Cream 1%, Winlevi 1% Cream, Winlevi 1% & Adapalene 0.3% Gel, Winlevi 1% & Duac Gel, Ctp-543, Brinzolamide Ophthalmic Suspension, Azopt, Tild Sub-Cutaneous Injection, Scd-044_Dose 1, Scd-044_Dose 2, Scd-044_Dose 3, Mm-Ii Dose I, Mm-Ii Dose Ii, Mm-Ii Dose Iii, Cequatm Ophthalmic Solution, Clindamycin Phosphate, Clindamycin Phosphate Rld, Tild, Etanercept, Tildrakizumab, Sdp-133, Lumigan, Part 2: Double-Blind Active Treatment Extension, Tildrakizumab, Injections Of Tildrakizumab, Sunpg18_07 I, Sunpg18_07 Ii, Zero-Dose, 90 Mcg Of Proair Hfa, 180 Mcg Of 90 Mcg Of Proair Hfa, 90 Mcg Of Albuterol Sulfate Inhalation Aerosol, Halobetasol Propionate, Treatment With Halobetasol Propionate 0.05% Topical Spray, Vehicle, Isv-305, Halobetasol Topical Lotion. These drug candidates are in various stages of clinical development as the company works toward FDA approval.